- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease Kuria...

- Kuria team to present potency, selectivity, and positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and...

- Kuria's Chief Operating Officer, Dr. Misty Stevens, to present company overview and host face-to-face booth presentation Kuria...

- Kuria's Chief Executive Officer Dr. Keith Ward to present company overview to premiere venture forum in the Southeast Kuria...

- Article by Kuria's Chief Executive Officer Dr. Keith Ward summarizes role of NRF2 pathway in corneal endothelial dysfunction Kuria...

- Kuria's Chief Executive Officer and Chief Development Officer to share ophthalmic program updates and present corporate overview Kuria...

- Chief Development Officer Dave Flory to present corporate overview and review Kuria's development plans for diseases of the cornea and...

Kuria's Chief Operating Officer, Dr. Misty Stevens, to present corporate overview and review Kuria's ophthalmic development plans Kuria...